Patients with EGFR-mutant advanced NSCLC receiving EGFR-TKIs have a median overall survival (OS) more than twice as long as those not receiving EGFR-TKIs (24.3 vs 10.8 months).[2] The 5-year survival rate of patients with EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs is 14.6%.[3] However, metastatic NSCLC patients with long-term survival (>10 years) are still rare. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.